As with other GLP-1 medications, orforglipron is not recommended for people with a personal or family history of thyroid tumors or multiple endocrine neoplasia type 2 (MEN2)
A 30 mg tirzepatide vial with 3 mL of bacteriostatic water makes 10 mg/mL, where 5 mg draws 50 units and 10 mg draws 100 units
RELATED: How Nicotinamide Riboside (NR) Is Linked to Increased NAD Levels and Healthy Aging Manufacturers declared adequate supply, and the agency sent cease-and-desist notices: stop making these compounds, you have 90 days
GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators
While berberine may offer modest metabolic benefits, it works through different mechanisms and produces smaller glycemic improvements than prescription GLP-1 medications, which remain the evidence-based standard of care
Is It For You
.jpg)
